Cutia Therapeutics Statistics
Want to see HK:2487 full AI Analyst Report?
Cutia Therapeutics (2487) Stock Statistics & Valuation Metrics
Total Valuation
Cutia Therapeutics has a market cap or net worth of HKD 252.31M. The enterprise value is HKD 621.20M.
- Market Cap
- HKD 252.31M
- Enterprise Value
- HKD 621.20M
Share Statistics
Cutia Therapeutics has 376,583,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 376,583,700
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Cutia Therapeutics’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -25.31%.
- Return on Equity (ROE)
- -0.38
- Return on Assets (ROA)
- -0.26
- Return on Invested Capital (ROIC)
- -25.31%
- Return on Capital Employed (ROCE)
- -0.30
- Revenue Per Employee
- 1.25M
- Profits Per Employee
- -1.27M
- Employee Count
- 268
- Asset Turnover
- 0.26
- Inventory Turnover
- 3.96
Valuation Ratios
The current PE Ratio of Cutia Therapeutics is -0.72. Cutia Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -0.72
- PS Ratio
- 0.64
- PB Ratio
- 0.29
- Price to FCF
- -0.92
- Price to Operating Cash Flow
- -0.91
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Cutia Therapeutics had revenue of 336.15M and earned -340.19M in profits. Earnings per share was -1.03.
- Revenue
- 336.15M
- Gross Profit
- 195.79M
- Operating Income
- -308.61M
- Pretax Income
- -340.19M
- Net Income
- -340.19M
- EBITDA
- -265.23M
- Earnings Per Share (EPS)
- -1.03
Cash Flow
In the last 12 months, operating cash flow was -226.70M and capital expenditures -4.75M, giving a free cash flow of -231.46M billion.
- Operating Cash Flow
- -226.70M
- Free Cash Flow
- -231.46M
- Free Cash Flow per Share
- -0.64
Dividends & Yields
Cutia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -108.43%
- Earnings Yield
- -136.09%
Stock Price Statistics
- Beta
- 1.34
- 52-Week Price Change
- -90.06%
- 50-Day Moving Average
- 0.94
- 200-Day Moving Average
- 2.99
- Relative Strength Index (RSI)
- 37.69
- Average Volume (3m)
- 521.43K
Important Dates
Cutia Therapeutics upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Cutia Therapeutics as a current ratio of 3.87, with Debt / Equity ratio of 35.85%
- Current Ratio
- 3.87
- Quick Ratio
- 3.73
- Debt to Market Cap
- 0.19
- Net Debt to EBITDA
- -0.20
- Interest Coverage Ratio
- -32.62
Taxes
In the past 12 months, Cutia Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Cutia Therapeutics EV to EBITDA ratio is -1.51, with an EV/FCF ratio of -1.45.
- EV to Sales
- 1.01
- EV to EBITDA
- -1.51
- EV to Free Cash Flow
- -1.45
- EV to Operating Cash Flow
- -1.48
Balance Sheet
Cutia Therapeutics has HKD 626.38M in cash and marketable securities with HKD 274.17M in debt, giving a net cash position of HKD 352.21M billion.
- Cash & Marketable Securities
- HKD 626.38M
- Total Debt
- HKD 274.17M
- Net Cash
- HKD 352.21M
- Net Cash Per Share
- HKD 0.94
- Tangible Book Value Per Share
- HKD 1.94
Margins
Gross margin is 53.59%, with operating margin of -79.47%, and net profit margin of -84.59%.
- Gross Margin
- 53.59%
- Operating Margin
- -79.47%
- Pretax Margin
- -83.84%
- Net Profit Margin
- -84.59%
- EBITDA Margin
- -66.72%
- EBIT Margin
- -79.47%
Analyst Forecast
The average price target for Cutia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 35.47%
- EPS Growth Forecast
- 46.42%
Scores
- Smart Score
- 2
- AI Score
- 44

